Nine-valent human papillomavirus vaccine: great science, but will it save lives?
Mené sur 14 215 participantes âgées de 16 à 26 ans, cet essai international évalue, du point de vue de l'immunogénicité, de la sécurité et de la réduction de l'incidence de lésions précancéreuses ou cancéreuses du col de l'utérus, de la vulve ou du vagin, l'intérêt d'un vaccin nonavalent contre le papillomavirus humain par rapport à un vaccin quadrivalent
In The Lancet, Warner K Huh and colleagues1 report their final analysis of a randomised, double-blind trial of 14 215 women, aged 16–26 years, testing the quadrivalent human papillomavirus (qHPV; HPV types 6, 11, 16, and 18) vaccine compared with the nine-valent HPV (9vHPV; HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine. The women were recruited from 105 study sites located in 18 countries and received vaccination on day 1 and months 2 and 6. The 9vHPV vaccine consists of virus-like particles of HPV 6, 11, 16, and 18 (as found in the qHPV vaccine) and an additional five types, HPV 31, 33, 45, 52, and 58, combined with the adjuvant amorphous aluminium hydroxyphosphate sulphate.
The Lancet , commentaire, 2016